Abstract:A major gap in amyloid-centric theories of Alzheimer's disease (AD) is that even though amyloid fibrils per se are not toxic in vitro, the diagnosis of AD clearly correlates with the density of beta-amyloid (A{beta}) deposits. Based on our proposed amyloid degradation toxicity hypothesis, we developed a mathematical model explaining this discrepancy. It suggests that cytotoxicity depends on the cellular uptake of soluble A{beta} rather than on the presence of amyloid aggregates. The dynamics of soluble A{beta} in the cerebrospinal fluid (CSF) and the density of A{beta} deposits is described using a system of differential equations. In the model, cytotoxic damage is proportional to the cellular uptake of A{beta}, while the probability of an AD diagnosis is defined by the A{beta} cytotoxicity accumulated over the duration of the disease. After uptake, A{beta} is concentrated intralysosomally, promoting the formation of fibrillation seeds inside cells. These seeds cannot be digested and are either accumulated intracellularly or exocytosed. A{beta} starts aggregating on the extracellular seeds and, therefore, its concentration decreases in the interstitial fluid. The dependence of both A{beta} toxicity and aggregation on the same process -- cellular uptake of A{beta} -- explains the correlation between AD diagnosis and the density of amyloid aggregates in the brain. We tested the model using clinical data obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI), which included records of beta-amyloid concentration in the cerebrospinal fluid (CSF-A{beta}42) and the density of beta-amyloid deposits measured using positron emission tomography (PET). The model predicts the probability of AD diagnosis as a function of CSF-A{beta}42 and PET and fits the experimental data at the 95% confidence level. Our study shows that existing clinical data allows for the inference of kinetic parameters describing beta-amyloid turnover and disease progression. Each combination of CSF-A{beta}42 and PET values can be used to calculate the individual's cellular uptake rate, the effective disease duration, and the accumulated toxicity. We show that natural limitations on these parameters explain the characteristic distribution of the clinical dataset for these two biomarkers in the population. The resulting mathematical model interprets the positive correlation between the density of A{beta} deposits and the probability of an AD diagnosis without assuming any cytotoxicity of the aggregated beta-amyloid. Finally, to the best of our knowledge, this model is the first to mechanistically explain the negative correlation between the concentration of A{beta}42 in the CSF and the probability of an AD diagnosis.

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model

Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease

Meta‐analysis of high‐clearance anti‐amyloid immunotherapies trials in early Alzheimer’s disease: A significant clinical effect but a low benefit/risk ratio

Modulating Innate Immune Activation States Impacts the Efficacy of Specific Aβ Immunotherapy

Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated

The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer’s disease: a meta-analysis

Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer’s Disease

Towards the Integrative Theory of Alzheimer’s Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis

Microglial roles in Alzheimer's disease: An agent-based model to elucidate microglial spatiotemporal response to beta-amyloid

The Efficacy and Safety of Anti-Aβ Agents for Delaying Cognitive Decline in Alzheimer's Disease: a Meta-Analysis.

The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults

Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer's disease trials

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model

Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat

Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research

Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease

Exploring the Relationship Between Amyloid Burden and Depression in Pre-clinical Alzheimer's Disease

Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

Amyloid-β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects

Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer's disease

<i>In vivo</i> characterization of cerebrovascular impairment induced by amyloid peptide overload in glymphatic clearance system using swept-source optical coherence tomography